دورية أكاديمية
أعرض في EDS

Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption.

التفاصيل البيبلوغرافية
العنوان: Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption.
المؤلفون: Harigaya H; Department of Dental Anesthesiology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Chiba-Ohkuma R; Department of Biochemistry and Molecular Biology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Karakida T; Department of Biochemistry and Molecular Biology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Yamamoto R; Department of Biochemistry and Molecular Biology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Fujii-Abe K; Department of Dental Anesthesiology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Kawahara H; Department of Dental Anesthesiology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan., Yamakoshi Y; Department of Biochemistry and Molecular Biology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 12; Vol. 25 (14). Date of Electronic Publication: 2024 Jul 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Bone Resorption*/drug therapy , Drug Repositioning*/methods , Midazolam*/pharmacology , Reactive Oxygen Species*/metabolism , Osteoclasts*/drug effects , Osteoclasts*/metabolism , Cell Differentiation*/drug effects , Lipopolysaccharides*/pharmacology, Animals ; Mice ; p38 Mitogen-Activated Protein Kinases/metabolism ; Male ; Inflammation/drug therapy ; Inflammation/pathology ; RAW 264.7 Cells ; Macrophages/drug effects ; Macrophages/metabolism
مستخلص: Drug repositioning is a method for exploring new effects of existing drugs, the safety and pharmacokinetics of which have been confirmed in humans. Here, we demonstrate the potential drug repositioning of midazolam (MDZ), which is used for intravenous sedation, as an inhibitor of inflammatory bone resorption. We cultured a mouse macrophage-like cell line with or without MDZ and evaluated its effects on the induction of differentiation of these cells into osteoclasts. For in vivo investigations, we administered lipopolysaccharide (LPS) together with MDZ (LPS+MDZ) to the parietal region of mice and evaluated the results based on the percentage of bone resorption and calvaria volume. Furthermore, we examined the effects of MDZ on the production of reactive oxygen species (ROS) in cells and on its signaling pathway. MDZ inhibited osteoclast differentiation and bone resorption activity. In animal studies, the LPS+MDZ group showed a decreasing trend associated with the rate of bone resorption. In addition, the bone matrix volume in the LPS+MDZ group was slightly higher than in the LPS only group. MDZ inhibited osteoclast differentiation by decreasing ROS production and thereby negatively regulating the p38 mitogen-activated protein kinase pathway. Thus, we propose that MDZ could potentially be used for treating inflammatory bone resorption, for example, in periodontal disease.
References: Circ Res. 2010 Apr 16;106(7):1253-64. (PMID: 20185797)
Clin Oral Implants Res. 2012 Mar;23(3):263-73. (PMID: 21443592)
Redox Biol. 2016 Aug;8:186-91. (PMID: 26795736)
Antioxidants (Basel). 2021 Jun 01;10(6):. (PMID: 34205998)
Pharmaceutics. 2020 Mar 02;12(3):. (PMID: 32131534)
J Cell Mol Med. 2019 May;23(5):3077-3087. (PMID: 30892789)
J Periodontol. 2018 Jul;89(7):783-803. (PMID: 30133749)
Molecules. 2021 Jan 12;26(2):. (PMID: 33445451)
Handb Exp Pharmacol. 2008;(182):335-60. (PMID: 18175099)
Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(8):434-53. (PMID: 23060232)
Regen Ther. 2022 Jun 21;21:104-113. (PMID: 35785043)
Int J Mol Sci. 2019 Feb 04;20(3):. (PMID: 30720745)
FEBS Lett. 2000 Dec 1;486(1):23-8. (PMID: 11108836)
J Clin Periodontol. 2012 Jun;39(6):546-55. (PMID: 22519301)
FASEB J. 2017 Feb;31(2):781-792. (PMID: 27836987)
Folia Morphol (Warsz). 2021;80(4):972-979. (PMID: 33169355)
Ciba Found Symp. 1997;205:246-55; discussion 255-60. (PMID: 9189629)
Heliyon. 2023 Apr 19;9(5):e15583. (PMID: 37153438)
Ann Anat. 2021 Sep;237:151722. (PMID: 33771659)
Cytokine. 2001 Sep 21;15(6):320-7. (PMID: 11594799)
J Biol Chem. 2000 Oct 6;275(40):31155-61. (PMID: 10859303)
J Cell Biochem. 2007 Sep 1;102(1):98-109. (PMID: 17372917)
PLoS One. 2012;7(8):e37168. (PMID: 22720096)
Genes Cells. 2005 Dec;10(12):1139-51. (PMID: 16324151)
Clin Oral Investig. 2024 Apr 27;28(5):281. (PMID: 38676852)
Front Cell Neurosci. 2020 Dec 10;14:544431. (PMID: 33362467)
Clin Oral Investig. 2000 Jun;4(2):120-5. (PMID: 11218499)
J Biol Chem. 2004 Oct 29;279(44):45935-41. (PMID: 15322091)
Dent Mater J. 2010 Aug;29(4):403-10. (PMID: 20610874)
Ann N Y Acad Sci. 2006 Dec;1092:385-96. (PMID: 17308163)
Genesis. 2022 Sep;60(8-9):e23490. (PMID: 35757898)
J Dent Res. 2014 May;93(5):508-13. (PMID: 24603641)
BMC Complement Med Ther. 2022 Oct 14;22(1):272. (PMID: 36242028)
Pharmacol Rev. 1999 Dec;51(4):629-50. (PMID: 10581326)
Epidemiol Rev. 2017 Jan 1;39(1):49-58. (PMID: 28449041)
J Inflamm (Lond). 2022 Nov 30;19(1):24. (PMID: 36451220)
Bioengineered. 2021 Dec;12(1):2155-2163. (PMID: 34057023)
In Vitro Cell Dev Biol Anim. 2006 Jul-Aug;42(7):182-8. (PMID: 16948499)
J Mol Cell Cardiol. 2016 Dec;101:11-24. (PMID: 27838370)
معلومات مُعتمدة: JP21K09945 Japan Society for the Promotion of Science; JP22K10027 Japan Society for the Promotion of Science
فهرسة مساهمة: Keywords: bone resorption; drug repositioning; inflammation; midazolam; reactive oxygen species; signal transduction
المشرفين على المادة: R60L0SM5BC (Midazolam)
0 (Reactive Oxygen Species)
0 (Lipopolysaccharides)
EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11277201
DOI: 10.3390/ijms25147651
PMID: 39062893
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25147651